so hard to judge at this early value.Things to remember though,...

so hard to judge at this early value.

Things to remember though, are
1. The product works and is effective in doing what it does
2. It is unique and nothing on the market currently available can do what it does
3. It has approval in many of the bigger 'health' centres of the world ( US/AUS/KOREA and others)
4. Distribution network arrange/being better arranged.
5. Already making sales in multiple countries
6. Free air time on National TV in the US (you would probably be paying 1/10th of the market cap of KSX to have such well trusted experts do a payed equivalent of the advertising we got on TV)


I'm not sure about Takeovers and what not because I dont know if other distribution companies would want to have such an early stage product that they had to spruike, but either way this is a good product for health care